Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)
August 7, 2025 10:44 AM EDTRaymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).
The analyst comments "EWTX reported 2Q financial results and provided a corporate update. Timing for key catalysts remains on track. We continue to believe that EWTX offers among the most attractive risk/reward skews in our coverage universe into CIRRUS-HCM Part D results (beginning in 4Q25); we reiterate our Strong Buy rating. Update from EDG-7500 Phase 2 CIRRUS-HCM Part D (12-week) expected in 4Q25. EWTX previously reported 4-week Phase 2 CIRRUS-HCM (Parts B/C) data in... More
